Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctiOn by Rimonabant: The effectiveness in daily practice and its USE)

Family Practice

Volumn 29, Issue 5, 2012, Pages 521-527

  Boesten, Jolien E J ^a   Kaper, Janneke ^a   Stoffers, Henri E J H ^a   Kroon, Abraham A ^b   Van schayck, Onno C P ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Cardiovascular disorders; Diabetes; Drug reactions; Hypertension; Insulin resistance; Pharmacology; Primary care; Quality of life

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RIMONABANT;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTICE; HEALTH CARE; HUMAN; HYPERGLYCEMIA; HYPOTHESIS; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; QUALITY OF LIFE; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; AGED; ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; COUNSELING; DOUBLE-BLIND METHOD; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; OBESITY; OUTCOME ASSESSMENT (HEALTH CARE); PIPERIDINES; PRIMARY HEALTH CARE; PYRAZOLES; QUALITY OF LIFE; RISK REDUCTION BEHAVIOR; SAFETY-BASED DRUG WITHDRAWALS; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84867135023     PISSN: 02632136     EISSN: 14602229     Source Type: Journal    
DOI: 10.1093/fampra/cms013     Document Type: Article

References (20)

1. Branca F, Nikogosian H, Lobstein T. The Challenge of Obesity in the WHO European Region and the Strategies for Response. Copenhagen, Denmark: WHO Library Cataloguing in Publication Data, 2007.
2. Cannon C. Obesity-related cardiometabolic complications. Clin Cornerstone 2008; 9: 11-22.
3. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-209.
4. Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med 2006; 12: 75-80.
5. Stalman WAB, Scheltens T, Burgers JS et al. NHG-Standaard Cardiovasculair risicomanagement. Utrecht, The Netherlands: Houten: Bohn Stafleu van Loghum, 2006.
6. Padwal RS, Majumdar SR. New drug class drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-7.
7. Despres J-P, Golay A, Sjörström L. the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-34.
8. Pi-Sunyer FX, Aronne LJ, Heshmati HM et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-75.
9. Scheen AJ, Finer N, Hollander P et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-72.
10. Van Gaal LF, Rissanen AM, Scheen AJ et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-97.
11. Martin K, Begaud B, Latry P et al. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 2003; 57: 86-92.
12. Le Foll B, GorelickDA, GoldbergSR. The future of endocannabinoidoriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009; 205: 171-4.
13. Metsemakers JFM, Höppener P, Knottnerus JA, Kocken RJJ, Limonard CBG. Computerized health information in The Netherlands: a registration network of family practices. Br J Gen Pract 1992; 42: 102-6.
14. Rutten Gehm, De Grauw WJC, Goudswaard AN et al. NHGStandaard Diabetesmellitus type 2 (Tweede herziening).Huisarts Wet 2006; 3: 137-52.
15. Stevens RJ, Kothari V, Adler AI et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001; 101: 671-9.
16. Aaronson NK, Muller M, CohenPDAet al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998; 51: 1055-68.
17. Brooks R, EuroQol group. EuroQol: the current state of play. Health Policy 1996; 37: 53-72.
18. Glasser SP, Salas M, Delzell E. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. J Clin Pharmacol 2007; 47: 1074-86.
19. IdelevichE, KirchW, SchindlerC. Current pharmacotherapeutic concepts for the treatment of obesity in adults. Ther Adv Cardiovasc Dis 2009; 3: 75-90.
20. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated metaanalysis. BMJ 2007; 335: 1194-9.